Zhu Wang1, Hailong Zhang, He Zhao, Xiaoze Wang, Jiaywei Tsauo, Xuefeng Luo, Xiao Li. 1. Institution of Interventional Radiology, West China Hospital, Sichuan University, Sichuan, China; Department of Gastroenterology, West China Hospital, Sichuan University, Sichuan, China. simonlixiao@126.com.
Abstract
PURPOSE: We aimed to investigate the safety and long-term outcomes of repeated transcatheter arterial chemoembolization (TACE) in cirrhotic patients with transjugular intrahepatic portosystemic shunt (TIPS). METHODS: Data of patients with hepatocellular carcinoma, who had previous TIPS implantation and received TACE between January 2010 and December 2012, were reviewed retrospectively. The primary outcome measure was liver function, which was represented by model for end-stage liver disease score, Child-Pugh-Turcotte score, serum total bilirubin, alanine aminotransferase, and aspartate aminotransferase. Changes in liver function before and after the initial TACE procedure and hepatobiliary severe adverse events (SAEs) were compared. Liver function following the initial TACE session was compared with that obtained in later TACE sessions. The secondary outcome measures were tumor response to multiple TACE sessions and survival. RESULTS: Seventeen patients underwent at least two TACE sessions, while nine patients underwent at least three sessions during the follow-up period. There was no statistically significant difference between the liver function tests performed before and one-month after the TACE procedure. Grade 3 or 4 SAEs occurred in six (31.6 %) patients within one month. The one, two-, and three-year survival rates were 88%, 53%, and 32%, respectively. Tumor response of multiple TACE sessions was the only predictive risk factor of mortality (OR=4.40; P = 0.030; 95% CI, 1.15-16.85). CONCLUSION: Our results suggest that repeated TACE is safe in selected patients with TIPS.
PURPOSE: We aimed to investigate the safety and long-term outcomes of repeated transcatheter arterial chemoembolization (TACE) in cirrhoticpatients with transjugular intrahepatic portosystemic shunt (TIPS). METHODS: Data of patients with hepatocellular carcinoma, who had previous TIPS implantation and received TACE between January 2010 and December 2012, were reviewed retrospectively. The primary outcome measure was liver function, which was represented by model for end-stage liver disease score, Child-Pugh-Turcotte score, serum total bilirubin, alanine aminotransferase, and aspartate aminotransferase. Changes in liver function before and after the initial TACE procedure and hepatobiliary severe adverse events (SAEs) were compared. Liver function following the initial TACE session was compared with that obtained in later TACE sessions. The secondary outcome measures were tumor response to multiple TACE sessions and survival. RESULTS: Seventeen patients underwent at least two TACE sessions, while nine patients underwent at least three sessions during the follow-up period. There was no statistically significant difference between the liver function tests performed before and one-month after the TACE procedure. Grade 3 or 4 SAEs occurred in six (31.6 %) patients within one month. The one, two-, and three-year survival rates were 88%, 53%, and 32%, respectively. Tumor response of multiple TACE sessions was the only predictive risk factor of mortality (OR=4.40; P = 0.030; 95% CI, 1.15-16.85). CONCLUSION: Our results suggest that repeated TACE is safe in selected patients with TIPS.
Authors: H Sakaguchi; H Uchida; M Maeda; N Matsuo; K Kichikawa; H Ohishi; H Nishida; K Ueno; K Nishimine; J Rösch Journal: Cardiovasc Intervent Radiol Date: 1995 Jan-Feb Impact factor: 2.740
Authors: Eva Knüppel; Dominik Bettinger; Wulf Euringer; Robert Thimme; Martin Roessle; Hans Christian Spangenberg; Michael Schultheiβ Journal: Hepatology Date: 2013-10-21 Impact factor: 17.425
Authors: Laura Marelli; Rosa Stigliano; Christos Triantos; Marco Senzolo; Evangelos Cholongitas; Neil Davies; Jonathan Tibballs; Tim Meyer; David W Patch; Andrew K Burroughs Journal: Cardiovasc Intervent Radiol Date: 2007 Jan-Feb Impact factor: 2.740
Authors: E Caturelli; D A Siena; S Fusilli; M R Villani; G Schiavone; M Nardella; S Balzano; F Florio Journal: Radiology Date: 2000-04 Impact factor: 11.105
Authors: John T Miura; William S Rilling; Sarah B White; Robert A Hieb; Sean M Tutton; Parag J Patel; T Clark Gamblin; Eric J Hohenwalter Journal: HPB (Oxford) Date: 2015-08 Impact factor: 3.647